Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

Presentation TCT 2023

TCT 649: Impact of a Novel Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) on Below-the-knee Atherosclerotic Disease: 2023 Update

Presenter: Terumitsu Hasebe

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

Presentation TCT 2023

TCT 74: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With In-stent Restenosis in Small Coronary Arteries.

Presenter: Wojciech Wanha

October 24, 2023

Presentation TCT 2023

TCT 60: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis in Chronic Coronary Syndrome (CCS Dragon-Registry)

Presenter: Wojciech Wanha

October 24, 2023

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

Presentation TCT 2019

PICCOLETO II: 6-Month Clinical and Angiographic Findings From a Randomized Trial of Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Small Vessel Coronary Artery Disease

Presenter: Bernardo Cortese

September 27, 2019

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

Presentation TCT 2018

Drug-Eluting Stents For Tibial Disease: Data and Case Examples

Presenter: Ehrin J. Armstrong, Sahil A. Parikh, Robert A. Lookstein

September 22, 2018

Presentation TCT 2018

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

Presenter: William A. Gray

September 22, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Advertisement

What’s Going to Be Hot at TCT 2025

What’s Going to Be Big at TCT 2024?

TCT 649: Impact of a Novel Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) on Below-the-knee Atherosclerotic Disease: 2023 Update

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

TCT 74: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With In-stent Restenosis in Small Coronary Arteries.

TCT 60: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis in Chronic Coronary Syndrome (CCS Dragon-Registry)

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

PICCOLETO II: 6-Month Clinical and Angiographic Findings From a Randomized Trial of Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Small Vessel Coronary Artery Disease

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Drug-Eluting Stents For Tibial Disease: Data and Case Examples

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content